NL-OMON39287RecruitingNot Applicable
Application of PET-MR- a diagnostic accuracy study of combined dwMRI and 18F-Choline PET-CT for baseline staging of prostate cancer validated by extended laparoscopic lymph node dissection. - PET-MR for prostate cancer staging
Isala Klinieken0 sites45 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 45
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational invasive
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •1. Age 18-80
- •2. Written informed consent
- •3. Biopsy proven prostate cancer cT1-T3 Nx M0
- •4. A chance of more than 15% of having lymph node metastases
Exclusion Criteria
- •1. Neo-adjuvant treatments for prostate cancer .
- •2. Severe claustrophobia
- •3. Any metal prosthesis or device
Investigators
Similar Trials
Recruiting
Not Applicable
Evaluation of the value of PET/MRI for diagnosis and treatment monitoring of patients with ankylosing Spondylitis before and after Treatment with a TNF-blockerM45.09DRKS00016917MSD Deutschland10
Completed
Phase 1
A PET (positron emission tomography) clinical research study using prostate specific membrane antigen (PSMA) targeted tracer, 89Zr-Df-IAB2MProstate cancer / Urothelial carcinoma / Renal cell carcinoma / Testicular cancerJPRN-UMIN000015356niversity of Tsukuba15
Unknown
Not Applicable
Assessment of the Accuracy of PET/MR in Detection and Monitoring Response of Bone MetastasesBone MetastasesNCT04159376Tel-Aviv Sourasky Medical Center150
Withdrawn
Not Applicable
PET/MRI in Endometrial CancerCytoreductive SurgeryGrade 3 Endometrial Endometrioid AdenocarcinomaHigh Grade Serous CarcinomaEndometrial Undifferentiated CarcinomaEndometrial Mixed Cell AdenocarcinomaNCT05390021Massachusetts General Hospital
Terminated
Not Applicable
Validation of Combined PET-MR Quantitative Parameters for Cardiac ApplicationsCardiac DiseaseNCT02062008University of California, San Francisco2